MNG599
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.450
- KRAS_SIGNALING_DN+0.360
- SPERMATOGENESIS+0.229
- MYOGENESIS+0.030
- COAGULATION-0.006
- BILE_ACID_METABOLISM-0.085
- APICAL_SURFACE-0.113
- XENOBIOTIC_METABOLISM-0.141
- KRAS_SIGNALING_UP-0.172
- APICAL_JUNCTION-0.189
Top 10 suppressed
- PROTEIN_SECRETION-0.623
- UNFOLDED_PROTEIN_RESPONSE-0.571
- MYC_TARGETS_V2-0.568
- TGF_BETA_SIGNALING-0.565
- MTORC1_SIGNALING-0.559
- MITOTIC_SPINDLE-0.552
- MYC_TARGETS_V1-0.519
- G2M_CHECKPOINT-0.515
- TNFA_SIGNALING_VIA_NFKB-0.493
- ANDROGEN_RESPONSE-0.482
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1246 | — | — | 0.979 |
| 2 | 8ad884fa-e426-4bc0-960d-08db42d341da | — | — | 0.977 |
| 3 | 08e3d239-3d8a-4eee-9e08-ac2bcb3f2619 | — | — | 0.976 |
| 4 | MDT-AP-0706 | Med | Medulloblastoma | 0.976 |
| 5 | MNG597 | — | — | 0.976 |
| 6 | TCGA-CF-A3MF-01A-12R-A21D-07 | — | — | 0.976 |
| 7 | msclc569389_S35.txt | — | cohortMD1 | 0.975 |
| 8 | c7d31245-5d71-4a23-8a33-4f83c4718e20 | — | — | 0.973 |
| 9 | SRR8942981 | — | — | 0.968 |
| 10 | SRR12696761 | — | — | 0.968 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 4 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.450 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.360 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.229 | Inavolisib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |